Investigational drug · Phase 2
DNA Vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Triple Negative Breast Cancer, Malignant Melanoma, Melanoma (Skin).
Phase 2Last checked: Nov 20, 2026Latest source record: May 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
496
Any phase or sponsor naming "DNA Vaccine"
First trial start
2019
Aug 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DNA Vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer
- Malignant Melanoma
- Melanoma (Skin)
- Melanoma Stage III
- Melanoma Stage IV
Approved drugs for the same conditions: Breast cancer · Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "DNA Vaccine" as an intervention, largest first.
AstraZenecaAstraZeneca (AZN)
NCT05126992 · 5,321,930 participants · Start Feb 18, 2022 · Primary completion Jan 24, 2024
Drug: AZD1222 · For: COVID-19, Vaccine Adverse Events of Special Interest
Sites: Utrecht, Netherlands; Barcelona, Spain; Valencia, Spain · 4 sites in all
Kaiser PermanenteAcademic, hospital or other
NCT03694392 · 2,776,278 participants · Start Sep 16, 2018 · Primary completion Apr 9, 2021
Drug: Flublok Quadrivalent; Standard Dose Inactivated Influenza Vaccine (SD-IIV) · For: Influenza; Pneumonia; Lower Respiratory Tract Infection and 3 more
Sites: Oakland, California
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01600079 · 1,505,647 participants · Start May 15, 2012 · Primary completion Oct 16, 2020
Drug: ZOSTAVAX™ · For: Herpes Zoster; Shingles
Rwanda Biomedical CentreAcademic, hospital or other
NCT06536855 · 100,000 participants (planned) · Start Sep 1, 2024 · Primary completion Mar 30, 2025
Drug: Gardasil 9 · For: Cervical Cancer
Shabir MadhiAcademic, hospital or other
NCT04914832 · 75,012 participants · Start Aug 30, 2021 · Primary completion Sep 30, 2022
Drug: AZD1222 · For: COVID-19; Pneumonia, Viral
Sites: Mbabane, Eswatini
- Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04516746 · 32,450 participants · Start Aug 28, 2020 · Primary completion Mar 5, 2021
Drug: AZD1222; Placebo · For: COVID-19; SARS-CoV-2
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 84 sites in all
Masaryk UniversityAcademic, hospital or other
NCT04834869 · 30,000 participants (planned) · Start Apr 1, 2021 · Primary completion Dec 31, 2025
Drug: BNT162b2; mRNA-1273 and 8 more · For: Adverse Reaction to Vaccine; COVID19 Vaccine
Sites: Philadelphia, Pennsylvania; Hamilton, Canada; Split, Croatia · 14 sites in all
- EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19Pivotal-lookingStatus unknown
Federal University of Espirito SantoAcademic, hospital or other
NCT05059106 · 29,637 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 1, 2022
Drug: Half dose of ChAdOx1 nCoV-19 (AZD1222); Standard dose of ChAdOx1 nCoV-19 (AZD1222) · For: SARS-CoV-2
Sites: Vitória, Brazil
- A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and AbovePivotal-lookingStatus unknown
Walvax Biotechnology Co., Ltd.Industry
NCT04847102 · 28,000 participants (planned) · Start Jul 22, 2021 · Primary completion Nov 30, 2021
Drug: SARS-CoV-2 mRNA Vaccine; Placebo · For: COVID-19; SARS-CoV-2
Sites: Jakarta, Indonesia; Acapulco, Mexico; Cancún, Mexico · 12 sites in all
- Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO StudyPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03180034 · 27,945 participants · Start Nov 29, 2017 · Primary completion Aug 21, 2025
Drug: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed; Recombinant Human Papillomavirus Bivalent Vaccine and 1 more · For: Human Papillomavirus Infection; Human Papillomavirus-Related Cervical Carcinoma
Sites: Liberia, Costa Rica
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy.
Aparicio B, Silva L, Ruiz M, et al. · Oncoimmunology 2026
- Genetically engineered M13 phage-mediated H9N2 DNA vaccine with enhanced mucosal and systemic immune responses in mice.
Wang X, Zhao Z, Shi M, et al. · Drug Deliv 2026
- The development of DNA delivery system based on ionic liquid and carboxylic acid modified polyethyleneimine.
Thant Y, Watcharavongtip P, Jermsutjarit P, et al. · Drug Deliv 2026
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.
Morgado-Cáceres P, Hofmann-Vega F, Figueroa D, et al. · Oncoimmunology 2026
- Concurrent Schistosoma mansoni infection suppresses induction of HIV-1 Env-specific antibodies in a DNA-MVA-gp140 Env vaccine regimen in rhesus macaques.
Chege GK, Chapman RE, Mzukwa A, et al. · Hum Vaccin Immunother 2026
- A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.
Tenbusch M, Koopman G, Mooij P, et al. · J Med Primatol 2026
Also in development for Triple Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- FDA018-ADCPhase 31 trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.